Project Grant R01CA292503
Award Date
8/6/24
Completion Date
7/31/29
Dollars Obligated
$441K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award of $542,663 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Texas MD Anderson Cancer Center supports research aimed at developing novel targeted therapies for acute myeloid leukemia (AML) with MLL rearrangement or mutant NPM1. The key objectives are to: Determine the preclinical efficacy of BRG1/BRM antagonists, including an inhibitor (FHD-286) and a degrader (AU15330), and assess their impact on the epigenome,...
The National Cancer Institute (NCI) awarded the Icahn School of Medicine at Mount Sinai a $237,023 Project Grant under the Cancer Biology Research (CFDA 93.396) program to develop a scalable and cost-effective single-cell multi-omic profiling method (SHARE-ME-SEQ). This method will jointly capture gene expression, chromatin accessibility, and DNA methylation at the single-cell level, with the goal of identifying and targeting methylation-driven pathways in acute myeloid leukemia (AML). The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $662,938 to Northwestern University to conduct research aimed at understanding the role of gain-of-function mutant p53 proteins in regulating leukemia-initiating cell self-renewal, chromatin accessibility, and 3D chromatin structure. The overarching objective is to elucidate the mechanisms by which these mutant p53 proteins promote leukemogenesis and mediate therapy resistance...
The National Cancer Institute (NCI) awarded a $680,334 Project Grant under the Cancer Biology Research (CFDA 93.396) federal grant program to the Icahn School of Medicine at Mount Sinai (ISMMS). The 5-year grant, which began on March 1, 2025, aims to elucidate the specific molecular mechanisms and cellular players driving age-associated pro-tumoral myelopoiesis. The research will involve high-dimensional profiling of tumors from an early-stage lung cancer patient cohort, multi-omics...
This federal Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research to identify chemical compounds that inhibit the chromatin reader SGF29, a regulator of oncogenic transcription factors in acute myeloid leukemia (AML). The $768,437 award to the Sanford Burnham Prebys Medical Discovery Institute will fund the development and implementation of high-throughput screening assays to discover SGF29 inhibitors, which...
This federal Project Grant award, totaling $545,170, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports research to develop a targeted therapy for acute myeloid leukemia (AML) with the chromosome inversion inv(16). The research aims to characterize the therapeutic potential of an eIF4G1 inhibitor, SBI-756, in combination with the previously developed CBFB-SMMHC inhibitor AI-10-49, to overcome drug resistance in...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $444,952 to the University of California, San Diego (UCSD) to explore the impact of APOBEC3C and ADAR1 base deaminase deregulation on the progression of myeloproliferative neoplasms (MPNs) to secondary acute myeloid leukemia (sAML). The research aims to elucidate how DNA and RNA editing deregulation drives cancer stem cell generation and therapeutic resistance. Key elements include...
This federal Project Grant award of $160,642 from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports research by Weill Medical College of Cornell University to characterize the role of oncogenic NRAS mutations in isocitrate dehydrogenase (IDH) mutant acute myeloid leukemia (AML) leukemogenesis and therapeutic responsiveness. The research aims to define the mechanistic contribution of NRAS to IDH mutant AML and investigate how NRAS modulates...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $695,464 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct research aimed at uncovering the genetic and biological mechanisms underlying the development of B-cell acute lymphoblastic leukemia (B-ALL) in children. The research will integrate results from a large multi-ancestry genome-wide association study (GWAS) of childhood ALL with...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $483,760 to The Trustees of the University of Pennsylvania to conduct research on the role of the DCAF15 protein in acute myeloid leukemia (AML). The key objectives are to: (a) investigate the biological function of DCAF15 in myeloid development and leukemia in vivo, (b) examine the role of cohesin acetylation in AML pathogenesis, and (c) develop small molecule degraders targeting DCAF15....